$CPIX
CUMBERLAND PHARMACEUTICALS INC

2023 Q3 Form 10-Q Financial Statement

#000162828023029112 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $10.09M $10.89M
YoY Change -11.63% 5.73%
Cost Of Revenue $1.766M $1.521M
YoY Change -20.63% -25.15%
Gross Profit $8.320M $9.368M
YoY Change -9.45% 13.32%
Gross Profit Margin 82.49% 86.03%
Selling, General & Admin $7.087M $7.042M
YoY Change 12.91% 4.16%
% of Gross Profit 85.18% 75.17%
Research & Development $1.925M $1.145M
YoY Change 12.28% -37.21%
% of Gross Profit 23.13% 12.22%
Depreciation & Amortization $1.246M $1.201M
YoY Change -19.32% -25.79%
% of Gross Profit 14.98% 12.82%
Operating Expenses $9.012M $8.187M
YoY Change 12.78% -4.63%
Operating Profit -$1.867M $22.86K
YoY Change 546.81% -101.24%
Interest Expense $110.1K $192.6K
YoY Change -26.29% 39.97%
% of Operating Profit 842.71%
Other Income/Expense, Net $821.8K $981.8K
YoY Change 60.6%
Pretax Income -$1.056M $869.1K
YoY Change 153.71% -164.01%
Income Tax $6.938K $6.937K
% Of Pretax Income 0.8%
Net Earnings -$1.049M $872.2K
YoY Change 156.78% -165.3%
Net Earnings / Revenue -10.4% 8.01%
Basic Earnings Per Share -$0.07 $0.06
Diluted Earnings Per Share -$0.07 $0.06
COMMON SHARES
Basic Shares Outstanding 14.37M shares 14.45M shares
Diluted Shares Outstanding 14.28M shares 14.55M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.51M $18.25M
YoY Change -5.29% 0.18%
Cash & Equivalents $18.51M $18.25M
Short-Term Investments
Other Short-Term Assets $1.971M $2.278M
YoY Change -47.28% -19.66%
Inventory $8.671M $10.93M
Prepaid Expenses
Receivables $12.62M $12.22M
Other Receivables $0.00 $0.00
Total Short-Term Assets $41.77M $43.67M
YoY Change -15.03% -0.17%
LONG-TERM ASSETS
Property, Plant & Equipment $377.4K $384.4K
YoY Change -23.1% -15.98%
Goodwill $914.0K $914.0K
YoY Change -52.71% -52.71%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.556M $2.607M
YoY Change 5.3% 2.78%
Total Long-Term Assets $45.98M $45.70M
YoY Change 10.49% -6.29%
TOTAL ASSETS
Total Short-Term Assets $41.77M $43.67M
Total Long-Term Assets $45.98M $45.70M
Total Assets $87.75M $89.38M
YoY Change -3.33% -3.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.82M $10.91M
YoY Change -6.02% 3.03%
Accrued Expenses $334.3K $320.8K
YoY Change 45.59% -37.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.33M $26.96M
YoY Change 7.99% 11.16%
LONG-TERM LIABILITIES
Long-Term Debt $12.92M $13.15M
YoY Change -26.99% -30.8%
Other Long-Term Liabilities $6.455M $6.954M
YoY Change -30.43% -30.88%
Total Long-Term Liabilities $6.455M $6.954M
YoY Change -76.07% -76.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.33M $26.96M
Total Long-Term Liabilities $6.455M $6.954M
Total Liabilities $52.10M $52.54M
YoY Change -0.36% -1.45%
SHAREHOLDERS EQUITY
Retained Earnings -$11.19M -$10.14M
YoY Change 27.66% 21.35%
Common Stock $47.19M $47.30M
YoY Change -0.73% -1.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.99M $37.16M
YoY Change
Total Liabilities & Shareholders Equity $87.75M $89.38M
YoY Change -3.33% -3.4%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.049M $872.2K
YoY Change 156.78% -165.3%
Depreciation, Depletion And Amortization $1.246M $1.201M
YoY Change -19.32% -25.79%
Cash From Operating Activities $1.237M $5.235M
YoY Change -53.08% 124.64%
INVESTING ACTIVITIES
Capital Expenditures $95.07K $96.81K
YoY Change -143.5% -156.09%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$95.07K -$96.81K
YoY Change -113.96% -43.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -882.6K -3.276M
YoY Change -55.67% 171.12%
NET CHANGE
Cash From Operating Activities 1.237M 5.235M
Cash From Investing Activities -95.07K -96.81K
Cash From Financing Activities -882.6K -3.276M
Net Change In Cash 258.9K 1.863M
YoY Change -80.46% 96.14%
FREE CASH FLOW
Cash From Operating Activities $1.237M $5.235M
Capital Expenditures $95.07K $96.81K
Free Cash Flow $1.141M $5.139M
YoY Change -60.0% 105.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Insured Event Gain Loss
InsuredEventGainLoss
0 usd
CY2022Q2 us-gaap Insured Event Gain Loss
InsuredEventGainLoss
611330 usd
us-gaap Insured Event Gain Loss
InsuredEventGainLoss
0 usd
us-gaap Insured Event Gain Loss
InsuredEventGainLoss
611330 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
192635 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
137624 usd
us-gaap Interest Expense
InterestExpense
378988 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
869091 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2753299 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6900 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13875 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13800 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
862154 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1364666 usd
us-gaap Profit Loss
ProfitLoss
1034440 usd
us-gaap Profit Loss
ProfitLoss
-2767099 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-10046 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-29046 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-29944 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-46226 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
872200 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1335620 usd
us-gaap Net Income Loss
NetIncomeLoss
1064384 usd
us-gaap Net Income Loss
NetIncomeLoss
-2720873 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.06
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.09
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.07
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.19
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.06
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.09
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.07
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.19
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14393711 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14688505 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14376260 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14689798 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14554264 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14688505 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14570798 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14689798 shares
us-gaap Profit Loss
ProfitLoss
1034440 usd
us-gaap Profit Loss
ProfitLoss
-2767099 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2456590 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3272085 usd
us-gaap Share Based Compensation
ShareBasedCompensation
188034 usd
us-gaap Share Based Compensation
ShareBasedCompensation
132148 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-476606 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-68334 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
7809 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4791 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
611330 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-944925 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5527690 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
232110 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2949443 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
804400 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1227030 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
534541 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4658782 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
259926 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1688143 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3817152 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2180038 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
179453 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164241 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
91808 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
50248 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13714489 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
39000000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
35000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1652990 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
349910 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
788295 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2710200 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8824251 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18216565 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
42601978 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
159901 usd
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
566043 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1402433 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40793403 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40793403 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-27753 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
196692 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1364666 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
39204292 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35974006 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
90156 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
187961 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
172286 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36048487 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36048487 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
97877 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
171616 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
862154 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36836902 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
872200 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1335620 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14393711 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14688505 shares
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
160553 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14554264 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14688505 shares
us-gaap Net Income Loss
NetIncomeLoss
1064384 usd
us-gaap Net Income Loss
NetIncomeLoss
-2720873 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14376260 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14689798 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
194538 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14570798 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14689798 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
413074 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
289975 shares
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10299152 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20113515 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21474197 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
100000 usd
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
200000 usd
us-gaap Sublease Income
SubleaseIncome
200000 usd
us-gaap Sublease Income
SubleaseIncome
300000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
500000 usd
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
6700000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
7500000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12859432 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12899659 usd
CY2023Q2 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
126753 usd
CY2022Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
168923 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4636673 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4322166 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
17622858 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
17390748 usd
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
6694452 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
7527167 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
10928406 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9863581 usd
CY2021Q4 cpix Lessee Operating Lease Rent Increase
LesseeOperatingLeaseRentIncrease
0.025
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6831502 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5218403 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
320837 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172910 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5477040 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4586301 usd
CY2023Q2 cpix Lease Liability
LeaseLiability
5797877 usd
CY2022Q4 cpix Lease Liability
LeaseLiability
4759211 usd
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
1800000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
422975 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
863320 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
836100 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
909911 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
934180 usd
CY2023Q2 cpix Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
5588192 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9554678 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3756801 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
226772 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
285963 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
501029 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
574071 usd
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
130842 usd
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
161804 usd
us-gaap Sublease Income
SubleaseIncome
245499 usd
us-gaap Sublease Income
SubleaseIncome
296237 usd
CY2017Q4 cpix Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities
StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
100000000 usd
CY2021Q4 cpix Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities
StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
19000000 usd
CY2022Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
16200000 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
44100000 usd
us-gaap Other Income
OtherIncome
2800000 usd
CY2023Q1 us-gaap Other Income
OtherIncome
1800000 usd
CY2023Q2 us-gaap Other Income
OtherIncome
1000000 usd

Files In Submission

Name View Source Status
0001628280-23-029112-index-headers.html Edgar Link pending
0001628280-23-029112-index.html Edgar Link pending
0001628280-23-029112.txt Edgar Link pending
0001628280-23-029112-xbrl.zip Edgar Link pending
a2023q2-exhibit311.htm Edgar Link pending
a2023q2-exhibit312.htm Edgar Link pending
a2023q2-exhibit321.htm Edgar Link pending
amendmentno3totheamendedan.htm Edgar Link pending
cpix-20230630.htm Edgar Link pending
cpix-20230630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
cpix-20230630_cal.xml Edgar Link unprocessable
cpix-20230630_lab.xml Edgar Link unprocessable
cpix-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cpix-20230630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cpix-20230630_def.xml Edgar Link unprocessable